icon-folder.gif   Conference Reports for NATAP  
 
  IDSA Conference
(Infectious Disease Society Association)
San Diego, CA Oct 17-21 2012
Back grey_arrow_rt.gif
 
 
 
Simeprevir (TMC435) in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection in treatment-na´ve and -experienced patients (PILLAR and ASPIRE Trials)
 
 
  Reported by Jules Levin
IDSA Oct 17-21 2012 San Diego
 
Ira Jacobson, MD,1 Michael Fried, MD,2 Peter Ferenci, MD,3 Igor Nikitin, MD,4 Fred Poordad, MD,5 Stefan Zeuzem, MD,6 Oliver Lenz, PhD,7 Vanitha Sekar, PhD,8 Monika Peeters, MSc,7 Goedele De Smedt, MD,7 and Maria Beumont-Mauviel, MD7
 
(1) Weill Medical College of Cornell University, New York, NY, USA; (2) University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; (3) Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria; (4) Russian State Medical University, Moscow, Russia; (5) Cedars-Sinai Medical Center, Los Angeles, CA, USA; (6) Gastroenterology, Klinikum der Johann-Wolfgang-Goethe-Universitat-Med. Klinik I, Frankfurt, Germany; (7) Janssen Infectious Diseases BVBA, Beerse, Belgium; (8) Janssen Research and Development LLC, Titusville, NJ, USA
 
IDSA: The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)

IDSA1.gif

IDSA2.gif

IDSA3.gif

IDSA4.gif

IDSA5.gif

IDSA6.gif

IDSA7.gif

IDSA8.gif

IDSA9.gif

IDSA10.gif

IDSA11.gif

IDSA12.gif

IDSA13.gif